Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Abstract: Biosimilars are hypothesized to contribute to lowering health care costs by entering the market at a discounted price compared with their reference biologics. Until recently, only filgrastim biosimilars...
Patients are not often given a voice in the development and implementation of clinical pathways, the main focus of which have been to provide treatment options and guidance primarily based on clinical medical...
Patients are not often given a voice in the development and implementation of clinical pathways, the main focus of which have been to provide treatment options and guidance primarily based on clinical medical...
Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....
Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....
All health care professionals recognize the Triple Aim, which is focused on outcomes, costs, and patient experiences. However, a fourth aim was added, which focuses on an essential, yet often forgotten, contribution...
All health care professionals recognize the Triple Aim, which is focused on outcomes, costs, and patient experiences. However, a fourth aim was added, which focuses on an essential, yet often forgotten, contribution...
In our increasingly digital world, providers’ and patients’ voices and individual needs must be prioritized. When it comes to treating others or being treated for incredibly complex illnesses, the health and...
In our increasingly digital world, providers’ and patients’ voices and individual needs must be prioritized. When it comes to treating others or being treated for incredibly complex illnesses, the health and...
Heart failure (HF) is the primary diagnosis in over 1 million hospitalizations annually,1 and patients who are hospitalized for HF are at high risk for all-cause hospital readmission, with a 1-month readmission rate...
Heart failure (HF) is the primary diagnosis in over 1 million hospitalizations annually,1 and patients who are hospitalized for HF are at high risk for all-cause hospital readmission, with a 1-month readmission rate...
The American Society of Clinical Oncology (ASCO) featured its Cancer Survivorship Symposium in Orlando, Florida from February 16-17, 2018. The meeting provided information about survivorship issues that both...
The American Society of Clinical Oncology (ASCO) featured its Cancer Survivorship Symposium in Orlando, Florida from February 16-17, 2018. The meeting provided information about survivorship issues that both...
The 2018 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium provides a forum for physicians and other members of the oncology care and research community who diagnose, treat, and...
The 2018 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium provides a forum for physicians and other members of the oncology care and research community who diagnose, treat, and...
ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors
The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for...
ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors
The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for...
The article, “Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs,” appearing in the November 2017 issue of Journal of Clinical Pathways, was updated for minor editorial additions and...
The article, “Longitudinal Study of Chronic Kidney Disease Progression and Associated Costs,” appearing in the November 2017 issue of Journal of Clinical Pathways, was updated for minor editorial additions and...
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.